IFNG (Human) Recombinant Protein
* The price is valid only in USA. Please select country.
-
More Files
- More Functions
Result of bioactivity analysis
Result of bioactivity analysis
IFNG (Human) Recombinant Protein stimulates cytotoxicity of the WiDr human colon colorectal adenocarcinoma cells. The ED50 range ≤ 5 ng/mL.
-
Specification
Product Description
Human IFNG (NP_000610, 24 a.a. - 161 a.a.) partial recombinant protein with His tag expressed in Escherichia coli.
Host
Human
Theoretical MW (kDa)
18.4
Form
Liquid
Preparation Method
Escherichia coli expression system
Purity
> 90% by SDS-PAGE
Endotoxin Level
> 1 EU per 1ug of protein (determined by LAL method)
Activity
Measured in a cytotoxicity assay using WiDr human colon colorectal adenocarcinoma cells. The ED50 range ≤ 5 ng/ml.
Quality Control Testing
3ug by SDS-PAGE under reducing condition and visualized by coomassie blue stain.
Recommend Usage
SDS-PAGE
The optimal working dilution should be determined by the end user.Storage Buffer
In PBS, pH 7.4 (20% glycerol)
Storage Instruction
Stored at 2°C to 8°C for 1 week.
For long term storage, aliquot and store at -20°C to -80°C.
Avoid repeated freezing and thawing cycles.Note
Result of bioactivity analysis
-
Applications
SDS-PAGE
-
Gene Info — IFNG
Entrez GeneID
3458Protein Accession#
NP_000610Gene Name
IFNG
Gene Alias
IFG, IFI
Gene Description
interferon, gamma
Gene Ontology
HyperlinkGene Summary
Interferon-gamma (IFNG), or type II interferon, is a cytokine critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. Aberrant IFNG expression is associated with a number of autoinflammatory and autoimmune diseases. The importance of IFNG in the immune system stems in part from its ability to inhibit viral replication directly, but most importantly derives from its immunostimulatory and immunomodulatory effects. IFNG is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by CD4 (MIM 186940) and CD8 (see MIM 186910) cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops (Schoenborn and Wilson, 2007 [PubMed 17981204]).[supplied by OMIM
Other Designations
-
-
Interactome
-
Pathway
-
Disease
- +1-909-264-1399
+1-909-992-0619
Toll Free : +1-877-853-6098 - +1-909-992-3401
- sales@abnova.com